Insulin Therapy: Types, Delivery Methods, and Management
Insulin therapy is the cornerstone of glucose management for people with type 1 diabetes and a critical intervention for type 2 diabetes when oral agents alone cannot maintain adequate glycemic control. This page covers the major insulin classifications, available delivery mechanisms, dosing frameworks, and the clinical decision boundaries that govern treatment escalation. Understanding how these elements interact is essential context for anyone navigating the broader landscape of endocrinology care or evaluating treatment options alongside a clinical team.
Definition and Scope
Insulin therapy refers to the exogenous administration of insulin — a peptide hormone produced by pancreatic beta cells — to replace or supplement endogenous insulin production. The U.S. Food and Drug Administration (FDA) regulates insulin products under the Federal Food, Drug, and Cosmetic Act, and beginning March 2020 the agency reclassified all previously "grandfathered" insulin products as biologics under the Biologics Price Competition and Innovation Act, requiring updated Biologics License Applications for continued marketing (FDA, Insulin Products Guidance).
The scope of insulin therapy spans four primary clinical populations:
- Type 1 diabetes — absolute insulin deficiency requiring continuous replacement
- Type 2 diabetes — relative deficiency after oral/non-insulin agents fail to maintain target HbA1c
- Gestational diabetes — when diet and exercise are insufficient to control blood glucose during pregnancy
- Hyperglycemia in hospitalized patients — including stress hyperglycemia and perioperative management
The American Diabetes Association (ADA) Standards of Care in Diabetes, updated annually in Diabetes Care, provide the primary evidence-based framework governing when insulin is initiated, intensified, or modified. For a full overview of how insulin therapy fits within the regulatory and clinical oversight structure governing endocrinology practice, see the regulatory context for endocrinology.
How It Works
Insulin lowers blood glucose by binding to insulin receptors on cell surfaces, triggering glucose uptake in skeletal muscle and adipose tissue while suppressing hepatic glucose output. In people with type 1 diabetes, endogenous production is absent; in type 2, progressive beta-cell failure reduces output over time.
Insulin products are classified by onset, peak, and duration of action — the three pharmacokinetic parameters that determine when a dose takes effect, when it reaches maximum activity, and how long it remains active.
Insulin Classification by Action Profile
| Class | Example Products | Onset | Peak | Duration |
|---|---|---|---|---|
| Rapid-acting analog | Lispro, Aspart, Glulisine | 10–30 min | 30–90 min | 3–5 hr |
| Short-acting (Regular) | Regular Human Insulin | 30–60 min | 2–4 hr | 6–8 hr |
| Intermediate-acting | NPH (Isophane) | 1–3 hr | 4–8 hr | 12–18 hr |
| Long-acting analog | Glargine, Detemir | 1–2 hr | Minimal peak | 20–24 hr |
| Ultra-long-acting analog | Degludec | 30–90 min | Flat profile | >42 hr |
| Inhaled rapid-acting | Technosphere Insulin (Afrezza) | ~12–15 min | ~30 min | ~3 hr |
Data on pharmacokinetic ranges drawn from FDA-approved prescribing information and summarized in the ADA Standards of Care.
The basal-bolus framework separates insulin into two functional roles: basal insulin (long- or ultra-long-acting) suppresses fasting hepatic glucose production, while bolus insulin (rapid- or short-acting) covers postprandial glucose excursions. This physiologic approach most closely mimics normal pancreatic function and is the standard of care for type 1 diabetes per ADA and the American Association of Clinical Endocrinology (AACE).
Common Scenarios
Type 1 Diabetes
All individuals with type 1 diabetes require insulin replacement from diagnosis. The standard regimen is multiple daily injections (MDI) — typically 4 or more injections per day — or continuous subcutaneous insulin infusion (CSII) via an insulin pump. The insulin pump and closed-loop systems page covers advanced pump technology including hybrid closed-loop systems that combine continuous glucose monitoring with automated basal rate adjustment.
Type 2 Diabetes Intensification
Per ADA Standards of Care, insulin initiation in type 2 diabetes is indicated when HbA1c remains above individualized targets (commonly ≥10% or symptoms of hyperglycemia are present) despite optimized non-insulin therapy. Basal insulin is typically introduced first — at a starting dose of 10 units per day or 0.1–0.2 units per kilogram body weight, according to ADA guidelines (ADA Standards of Care 2024, Section 9). Titration follows structured protocols, with fasting glucose as the primary target.
Gestational Diabetes and Pregnancy
Insulin is the preferred pharmacologic agent for gestational diabetes when glycemic targets are not met by nutrition therapy, as most oral agents lack sufficient safety data in pregnancy. NPH and rapid-acting analogs (lispro, aspart) have the most established safety profiles in this context, per guidance from the American College of Obstetricians and Gynecologists (ACOG).
Decision Boundaries
Clinical decisions about insulin type, regimen, and delivery method depend on several intersecting factors. The following numbered framework reflects major decision nodes used in endocrinology and diabetes management:
- Diagnosis type — Type 1 requires immediate full replacement; type 2 escalation follows a stepwise algorithm based on HbA1c and comorbidities.
- HbA1c target — Individualized targets range from <6.5% (stringent, low hypoglycemia risk) to <8.0% (relaxed, older adults or hypoglycemia-prone), per ADA.
- Hypoglycemia risk — History of severe hypoglycemia favors long-acting analogs over NPH (lower peak activity) and closed-loop delivery systems over open-loop MDI.
- Renal and hepatic function — Impaired clearance alters insulin half-life; dose reductions are required in advanced chronic kidney disease.
- Delivery method preference and access — Subcutaneous injection remains standard; inhaled insulin (Afrezza) is FDA-approved only as prandial coverage and is contraindicated in chronic lung disease. Insulin pump therapy requires structured patient training and is reviewed under diabetes technology.
- Biosimilar availability — Following FDA biologic reclassification, biosimilar insulins (e.g., Insulin Glargine-yfgn) are available and are evaluated for interchangeability on a product-specific basis by the FDA.
Glucose monitoring integration is a parallel decision boundary: continuous glucose monitoring (CGM) changes dosing adjustments and safety thresholds, particularly for patients on intensive basal-bolus regimens. The hemoglobin A1c and glucose monitoring and continuous glucose monitoring pages detail testing frameworks that directly inform insulin titration decisions.
Safety thresholds defined by the FDA's drug labeling requirements, AACE clinical practice guidelines, and the ADA Standards of Care collectively establish the outer boundaries of evidence-supported dosing — with any regimen requiring individualized adjustment by a licensed prescriber operating within those frameworks.
References
- U.S. Food and Drug Administration — Insulin Medicines to Treat Diabetes
- American Diabetes Association — Standards of Care in Diabetes 2024, Diabetes Care Supplement
- American Association of Clinical Endocrinology (AACE) — Diabetes Clinical Practice Guidelines
- American College of Obstetricians and Gynecologists (ACOG) — Gestational Diabetes Mellitus, Practice Bulletin
- FDA — Biosimilar and Interchangeable Insulin Products
- FDA Electronic Code of Federal Regulations — 21 CFR Part 601, Biologics Licensing
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)